Castle Biosciences (CSTL) EBIAT: 2018-2025
Historic EBIAT for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -$501,000.
- Castle Biosciences' EBIAT fell 122.08% to -$501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 301.42%. This contributed to the annual value of $18.2 million for FY2024, which is 131.75% up from last year.
- As of Q3 2025, Castle Biosciences' EBIAT stood at -$501,000, which was down 111.08% from $4.5 million recorded in Q2 2025.
- In the past 5 years, Castle Biosciences' EBIAT ranged from a high of $9.6 million in Q4 2024 and a low of -$29.2 million during Q1 2023.
- Over the past 3 years, Castle Biosciences' median EBIAT value was -$2.5 million (recorded in 2024), while the average stood at -$5.5 million.
- As far as peak fluctuations go, Castle Biosciences' EBIAT tumbled by 1,039.38% in 2023, and later soared by 471.71% in 2024.
- Castle Biosciences' EBIAT (Quarterly) stood at -$6.4 million in 2021, then crashed by 220.65% to -$20.6 million in 2022, then spiked by 87.49% to -$2.6 million in 2023, then spiked by 471.71% to $9.6 million in 2024, then plummeted by 122.08% to -$501,000 in 2025.
- Its EBIAT was -$501,000 in Q3 2025, compared to $4.5 million in Q2 2025 and -$25.8 million in Q1 2025.